Skip to main content

New-generation cardiac therapeutic strategies directed to the activation of endogenous regenerative mechanisms

Objective

Heart failure is a major epidemic world-wide, resulting in a large burden for society in deaths, morbidity and economic sustainability. The inability of the human heart to regenerate the myocardium lost due to acute myocardial infarction underlies a large part of chronic heart failure cases. To tackle this problem, REANIMA aims to deliver new therapies for heart regeneration, thereby reverting the conditions that lead to heart failure. Thus far, clinical trials based on introducing stem cells into the heart have not shown regenerative ability. In contrast, studies of spontaneous and induced heart regeneration in animal models strongly suggest a change in paradigm towards the reactivation of endogenous regenerative mechanisms. To develop this new path, REANIMA presents the first European basic-translational integrated effort in the cardiac regenerative field, with activities that span from the discovery of new targets in animal models to clinical trial design. REANIMA brings together knowledge on species that can regenerate their hearts –fish and amphibians–, animals that cannot regenerate their hearts –adult mammals– and human engineered heart tissues. Strong synergy between partners will allow REANIMA to identify new pathways in regenerative animals and design strategies for their reactivation in non-regenerative animals and human tissue. REANIMA incorporates industrial and academic partners specialised in translational and pre-clinical research, who will develop advanced therapeutic medicinal products and new translational platforms. REANIMA will thus establish a translational pipeline using cross-species gene/protein therapy products with high translational potential, thereby boosting the rapid transition from basic research to the design of clinical trials. We expect that REANIMA will change current paradigms underlying clinical efforts in regenerative cardiology by transforming basic knowledge on endogenous pathways into effective new therapies.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Single-Stage-RTD

Coordinator

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Net EU contribution
€ 1 380 000,00
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Other funding
€ 1 380 000,00

Participants (11)

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany
Net EU contribution
€ 780 000,00
Address
Martinistrasse 52
20251 Hamburg

See on map

Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 780 000,00
KING'S COLLEGE LONDON
United Kingdom
Net EU contribution
€ 780 000,00
Address
Strand
WC2R 2LS London

See on map

Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Other funding
€ 780 000,00
UNIVERSITAET BERN
Switzerland
Net EU contribution
€ 780 000,00
Address
Hochschulstrasse 6
3012 Bern

See on map

Region
Schweiz/Suisse/Svizzera Espace Mittelland Bern / Berne
Activity type
Higher or Secondary Education Establishments
Other funding
€ 780 000,00
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH
Austria
Net EU contribution
€ 780 000,00
Address
Campus-vienna-biocenter 1
1030 Wien

See on map

Region
Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 780 000,00
WEIZMANN INSTITUTE OF SCIENCE
Israel
Net EU contribution
€ 780 000,00
Address
Herzl Street 234
7610001 Rehovot

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 780 000,00
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
Netherlands
Net EU contribution
€ 780 000,00
Address
Kloveniersburgwal 29 Het Trippenhuis
1011 JV Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Other
Other funding
€ 780 000,00
ETHRIS GMBH
Germany
Net EU contribution
€ 450 000,00
Address
Semmelweisstr. 3
82152 Planegg

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Bayern Oberbayern München, Landkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 450 000,00
ZECLINICS SL
Spain
Net EU contribution
€ 250 000,00
Address
Ctra De Can Ruti, Cami De Les Escoles, S/n Laboratori P0-8, Edifici Igtp Muntanya
08916 Barcelona

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 250 000,00
DEUTSCHES PRIMATENZENTRUM GMBH
Germany
Net EU contribution
€ 710 000,00
Address
Kellnerweg 4
37077 Gottingen

See on map

Region
Niedersachsen Braunschweig Göttingen
Activity type
Research Organisations
Other funding
€ 710 000,00
SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA
Italy
Net EU contribution
€ 400 000,00
Address
Piazza Martiri Della Liberta 33
56127 Pisa

See on map

Region
Centro (IT) Toscana Pisa
Activity type
Higher or Secondary Education Establishments
Other funding
€ 400 000,00
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany
Net EU contribution
€ 130 000,00
Address
Hansastrasse 27c
80686 Munchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 130 000,00